Poolbeg Pharma (LON:POLB – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported GBX (0.28) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
Poolbeg Pharma Stock Performance
LON POLB opened at GBX 7.50 on Wednesday. The firm’s 50 day moving average price is GBX 8.04 and its two-hundred day moving average price is GBX 6.44. Poolbeg Pharma has a twelve month low of GBX 3.30 and a twelve month high of GBX 9.30. The stock has a market cap of £57.26 million, a price-to-earnings ratio of -7.98 and a beta of 1.83.
Analysts Set New Price Targets
Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday, September 24th.
About Poolbeg Pharma
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.
Featured Articles
- Five stocks we like better than Poolbeg Pharma
- The Bull Case for Amprius Technologies Just Got Stronger
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
